title: Valproate therapy and nonalcoholic fatty liver disease.
abstract: Nonalcoholic fatty liver disease was defined recently as another symptom of insulin resistance. Continuous therapy with valproate can result in increased body weight and insulin resistance, but no data are yet available on a possible relationship between valproate and nonalcoholic fatty liver disease. We here demonstrate in abdominal ultrasound investigations that characteristics of fatty liver disease were present in 61% of valproate-treated patients as compared with 23% receiving carbamazepine therapy.
authors.affiliation: Department of Neurology, Innsbruck University Hospital, Innsbruck, Austria. gerhard.luef@uibk.ac.at
authors.forename: Gerhard J
authors.initials: GJ
authors.lastname: Luef
authors.forename: Markus
authors.initials: M
authors.lastname: Waldmann
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Sturm
authors.forename: Anis
authors.initials: A
authors.lastname: Naser
authors.forename: Eugen
authors.initials: E
authors.lastname: Trinka
authors.forename: Iris
authors.initials: I
authors.lastname: Unterberger
authors.forename: Gerhard
authors.initials: G
authors.lastname: Bauer
authors.forename: Monika
authors.initials: M
authors.lastname: Lechleitner
mesh_terms: D000293:Adolescent; D000328:Adult; D002220:Carbamazepine / Q000627:therapeutic use; D016009:Chi-Square Distribution; D004827:Epilepsy / Q000188:drug therapy; D005234:Fatty Liver / Q000139:chemically induced* / Q000000981:diagnostic imaging*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D018709:Statistics, Nonparametric; D014463:Ultrasonography; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D002220:Carbamazepine; D014635:Valproic Acid